- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04295109
Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function
Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function in Patients Undergoing Laparoscopic Hysterectomy: a Double-blind, a Randomized Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Background: Patients often experience pain after gynecological laparoscopy. However, the use of opioid analgesia after surgery may increase the incidence of postoperative ileus (POI). Postoperative ileus (POI) is a common surgical emergency after a surgical procedure, leading to infection and intestinal adhesions, which can extend hospitalization and increase readmission rates, and consequently increasing healthcare costs. How to provide patients with ideal analgesia without affecting the recovery of postoperative gastrointestinal function? There is no guideline which has been troubling clinical anesthesiologists.
Aims: To observe the effects of fentanyl, oxycodone, Butorphanol on the recovery of gastrointestinal function after laparoscopic hysterectomy.
Methods: A total of 105 patients undergoing laparoscopic hysterectomy were randomly divided to three groups: fentanyl group(group F), butorphanol group(group B), or oxycodone group(group O). The primary outcome measures were postoperative time to first anal exhaust the total analgesic doses in PCIA,effective bolus times. Patients were also assessed for pain with a visual analogue scale (VAS), the cumulative PCIA dose, adverse effects (Nausea,vomiting, bradycardia, respiratory depression and pruritus), sedation level at 4, 12, 24, and 48 hours postoperatively, and satisfaction during the postoperative 48 hours and postoperative hospitalization days.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Cunming Liu, doctorate
- Phone Number: 13951890866
- Email: 1335587409@qq.com
Study Contact Backup
- Name: Minna Guo, Master
- Phone Number: 18835162576
- Email: 1653474602@qq.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- The First Affiliated Hospital with Nanjing Medical University
-
Contact:
- Cunming Liu
- Phone Number: 13951890866
- Email: 1335587409@qq.com
-
Contact:
- Minna Guo
- Phone Number: 18835162576
- Email: 1653474602@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients who were scheduled for laparoscopic hysterectomy from W&C BRANCH HOSPITAL OF JIANGSU PROVINCE HOSPITAL
- American Society of Anesthesiologists (ASA) physical status classification 1 to 2,
- Women aged 40-65
- Weight 50-80 kg
Exclusion Criteria:
- History of opioids abuse and allergy and contraindication to opioid drugs
- bronchial asthma; coronary heart disease; severe hypertension; diabetes mellitus;
- hepatic, and renal dysfunction (glutamyl aminotransferase> 40U or aspartate aminotransferase> 35U; urea nitrogen> 8.2 μmol / L, creatinine> 133 μmol / L),
- History of brain damage or psychiatric disease
- Patients with coagulopathy (PT> 17 seconds or activated partial thromboplastin time (APTT)> 47 seconds);
- pregnant or lactating women;
- Those with long-term constipation;
- History of digestive diseases;
- history of gastrointestinal disease (peptic ulcer disease, Crohn's disease, or ulcerative colitis)
- Participants in other drug trials in the past three months. (11)After randomization and allocation, patients were withdrawn if laparoscopy was converted to open surgery or if they required reinvestigation for postoperative bleeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Fentanyl group(group F)
Fentanyl citrate injection, specification: 10mL: 0.5mg / piece (production unit: niching chang rendu Pharmaceutical Co., Ltd., valid period: 48 months) For group F patients,0.5mg fentanyl was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
|
At present, opioids are most widely used in postoperative analgesia.
This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
Other Names:
|
Experimental: Oxycodone group(group O)
Oxycodone hydrochloride injection, specification: 1mL: 10mg / branch (production unit: HAMOL LIMITED, valid period: 60 months) For group O patients,30mg oxycodone was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
|
At present, opioids are most widely used in postoperative analgesia.
This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
Other Names:
|
Experimental: Butorphanol group(group B)
Butorphanol tartrate injection, specification: 1 mL: 1 mg / branch (production unit: Jiangsu henryi Pharmaceutical Co., Ltd., valid period: 24 months); For group B patients,10mg butorphanol was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
|
At present, opioids are most widely used in postoperative analgesia.
This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
postoperative time to first anal exhaust
Time Frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 15 days
|
Timing from the end of the operation
|
From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 15 days
|
the cumulative dose administered in the patient-controlled mode
Time Frame: From date of operation until the date of first documented progression of anal exhaust , assessed up to 48 hours
|
The cumulative dose administered in the patient-controlled mode during the initial 48 hours after the operation was measured
|
From date of operation until the date of first documented progression of anal exhaust , assessed up to 48 hours
|
effective bolus times
Time Frame: From date of operation until the date of first documented progression of anal exhaust , assessed up to 48 hours
|
The effective bolus times in the patient-controlled mode during the initial 48 hours after the operation was measured
|
From date of operation until the date of first documented progression of anal exhaust , assessed up to 48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pain score
Time Frame: at 4 hours postoperatively
|
by using numerical rating scale (NRS):The pain scale ranged from 0 (=no pain) to 10 (=worst pain imaginable)
|
at 4 hours postoperatively
|
pain score
Time Frame: at 12 hours postoperatively
|
by using numerical rating scale (NRS):The pain scale ranged from 0 (=no pain) to 10 (=worst pain imaginable)
|
at 12 hours postoperatively
|
pain score
Time Frame: at 24 hours postoperatively
|
by using numerical rating scale (NRS):The pain scale ranged from 0 (=no pain) to 10 (=worst pain imaginable)
|
at 24 hours postoperatively
|
pain score
Time Frame: at 48 hours postoperatively
|
by using numerical rating scale (NRS):The pain scale ranged from 0 (=no pain) to 10 (=worst pain imaginable)
|
at 48 hours postoperatively
|
Sedation score
Time Frame: at 4 hours postoperatively
|
by using Ramsay scale(1=anxious and agitated or restless, or both; 2=cooperative, oriented, and tranquil; 3=responds to command only; 4=asleep, but has a brisk response to light tactile stimulus or a simple verbal command; 5=asleep, but arousable only by strong physical stimulus; and 6=asleep, unarousable)
|
at 4 hours postoperatively
|
Sedation score
Time Frame: at 12 hours postoperatively
|
by using Ramsay scale(1=anxious and agitated or restless, or both; 2=cooperative, oriented, and tranquil; 3=responds to command only; 4=asleep, but has a brisk response to light tactile stimulus or a simple verbal command; 5=asleep, but arousable only by strong physical stimulus; and 6=asleep, unarousable)
|
at 12 hours postoperatively
|
Sedation score
Time Frame: at 24 hours postoperatively
|
by using Ramsay scale(1=anxious and agitated or restless, or both; 2=cooperative, oriented, and tranquil; 3=responds to command only; 4=asleep, but has a brisk response to light tactile stimulus or a simple verbal command; 5=asleep, but arousable only by strong physical stimulus; and 6=asleep, unarousable)
|
at 24 hours postoperatively
|
Sedation score
Time Frame: at 48 hours postoperatively
|
by using Ramsay scale(1=anxious and agitated or restless, or both; 2=cooperative, oriented, and tranquil; 3=responds to command only; 4=asleep, but has a brisk response to light tactile stimulus or a simple verbal command; 5=asleep, but arousable only by strong physical stimulus; and 6=asleep, unarousable)
|
at 48 hours postoperatively
|
adverse effects
Time Frame: at 4 hours postoperatively
|
Nausea 、vomiting 、bradycardia(HR <60 beats min-1)、respiratory depression(According to practice guidelines from the ASA, clinical signs of opioid-induced respiratory depression are respiratory rate <10 bpm, arterial O2 saturation <90%, or arterial CO2 tension >6.66 kPa) and pruritus
|
at 4 hours postoperatively
|
adverse effects
Time Frame: at 12 hours postoperatively
|
Nausea 、vomiting 、bradycardia(HR <60 beats min-1)、respiratory depression(According to practice guidelines from the ASA, clinical signs of opioid-induced respiratory depression are respiratory rate <10 bpm, arterial O2 saturation <90%, or arterial carbon dioxide (CO2)tension >6.66 kPa) and pruritus
|
at 12 hours postoperatively
|
adverse effects
Time Frame: at 24 hours postoperatively
|
Nausea 、vomiting 、bradycardia(HR <60 beats min-1)、respiratory depression (According to practice guidelines from the ASA, clinical signs of opioid-induced respiratory depression are respiratory rate <10 bpm, arterial O2 saturation <90%, or arterial CO2 tension >6.66 kPa)and pruritus
|
at 24 hours postoperatively
|
adverse effects
Time Frame: at 48 hours postoperatively
|
Nausea 、vomiting 、bradycardia(HR <60 beats min-1)、respiratory depression (According to practice guidelines from the ASA, clinical signs of opioid-induced respiratory depression are respiratory rate <10 bpm, arterial O2 saturation <90%, or arterial CO2 tension >6.66 kPa)and pruritus
|
at 48 hours postoperatively
|
patients' degree of overall satisfaction with the postoperative analgesia
Time Frame: at 48 hours postoperatively
|
Patients were asked to evaluate their degree of overall satisfaction with the postoperative analgesia on a 11-point scale (0= very unsatisfied, 1-3= unsatisfied, 4-6 = neutral, 7-9= satisfied, or 10 = very satisfied).
|
at 48 hours postoperatively
|
postoperative hospitalization days
Time Frame: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 15 days
|
All patients were cured in accordance with clinical cure standard
|
From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 15 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Cunming Liu, doctorate, The First Affiliated Hospital with Nanjing Medical University
- Study Chair: Shijiang Liu, Master, The First Affiliated Hospital with Nanjing Medical University
- Study Director: Chuanbao Han, The First Affiliated Hospital with Nanjing Medical University
- Study Chair: Minna Guo, The First Affiliated Hospital with Nanjing Medical University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Connective Tissue Diseases
- Neoplasms, Connective Tissue
- Neoplasms, Muscle Tissue
- Uterine Cervical Neoplasms
- Endometrial Neoplasms
- Adenomyosis
- Leiomyoma
- Myofibroma
Other Study ID Numbers
- 2019-SR-476
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancer
-
Assistance Publique - Hôpitaux de ParisUniversité Montpellier; Ecole d'econmie de Paris (PSE)-Hospinnomics; Université...CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage IIFrance
-
Radboud University Medical CenterMaastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsRecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IVNetherlands
-
Batman Training and Research HospitalEskisehir Osmangazi UniversityCompletedGynecologic Cancer | Endometrial Cancer Stage
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingAdvanced Endometrial CancerChina
-
Novartis PharmaceuticalsCompletedAdvanced Endometrial CancerBelgium, France, Italy, Canada, Spain, Australia, Germany, United States, Japan, Brazil, Singapore, Russian Federation, Poland
-
Rambam Health Care CampusCompletedSerous Papillary Endometrial CancerIsrael
-
Samsung Medical CenterRecruitingEndometrial Cancer Stage IKorea, Republic of
-
Duke UniversityDuke Cancer InstituteCompleted
-
Far Eastern Memorial HospitalCompletedOutcome of Endometrial CancerTaiwan
-
University of Southern DenmarkDanish Cancer Society; Region of Southern DenmarkRecruitingEmpowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROMDenmark
Clinical Trials on the drug of intravenous patient-controlled analgesia
-
Memorial Sloan Kettering Cancer CenterCompletedPostoperative PainUnited States
-
National Taiwan University HospitalUnknown
-
China-Japan Friendship HospitalRecruitingUniportal Video-assisted Thoracic SurgeryChina
-
Northern State Medical UniversityUniversity of TromsoCompletedCoronary Artery DiseaseRussian Federation
-
Pontificia Universidad Catolica de ChileCompletedHip Fractures | Perioperative Myocardial IschemiaChile
-
Feng XiaCompleted
-
Taipei City HospitalCompletedPain, Postoperative | Epidural Anesthesia | Lumbar Spine Degeneration | Analgesia, Patient-ControlledTaiwan
-
University Hospital OstravaCompletedHip Joint DisordersCzechia
-
Bursa Yüksek İhtisas Education and Research HospitalCompleted
-
University Health Network, TorontoWithdrawnAwake Craniotomy for Brain Tumour SurgeryCanada